Endovion

Drug Profile

Endovion

Alternative Names: NS 3728

Latest Information Update: 31 Aug 2016

Price : $50

At a glance

  • Originator NeuroSearch
  • Class Antineoplastics; Eye disorder therapies
  • Mechanism of Action Chloride channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Age-related macular degeneration; Cancer; Sickle cell anaemia

Most Recent Events

  • 31 Aug 2016 Chemical structure information added
  • 12 Jul 2016 Saniona in-licenses endovion from NeuroSearch before July 2016 (Saniona e-mail communication; July 2016)
  • 03 Jun 2016 Saniona plans a phase II trial for Colorectal cancer (Second-line therapy or greater, Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top